Experts map the real-world path to treating fear of cancer’s return

Fear of cancer recurrence is the shadow that follows millions of survivors long after treatment ends. New research published in Supportive Care in Cancer has taken a crucial step toward turning decades of psychological science into routine clinical practice, revealing exactly where the roadblocks lie and how to clear them. The study, led by Ben Smith of The Daffodil Centre and UNSW Sydney with colleagues across Australia, used a three-round Delphi survey of 89 health professionals and researchers to test whether a newly designed clinical pathway for fear of cancer recurrence could realistically be delivered in everyday care, not just in idealised trial conditions.

The scale of the problem is staggering. More than 53 million people worldwide are now living with and beyond cancer, and an international meta-analysis of 9,311 individuals found that 39 percent experience moderate fear of recurrence while 19 percent experience severe, clinically significant levels. That translates to more than 30 million people affected globally. Those with severe fear endure persistent preoccupation and worry, hypervigilance to every physical sensation, and genuine functional impairment, alongside poorer mental health, reduced quality of life, and heavier use of healthcare services. Receiving help with this fear has been identified as the single greatest unmet supportive care need among people with cancer.

What makes this gap so frustrating is that the science already exists. Validated screening instruments such as the Fear of Cancer Recurrence Inventory and the brief FCR-4/7 scales can identify who is struggling, and tested treatments including ConquerFear, Fear of Recurrence Therapy, and the SWORD blended cognitive behavioural therapy program have demonstrated real efficacy. Yet these tools rarely reach patients. Documented barriers include limited clinician awareness, inadequate referral pathways, equity concerns, workforce capacity constraints, and the difficulty of applying manualised interventions in the messy reality of diverse clinics. In 2024, Canadian guidelines and a complementary Australian clinical pathway finally offered formal guidance, both advocating routine screening followed by assessment and triage to stepped care.

The Australian team had already established, through a Delphi consensus process with 94 participants, that 35 of 38 proposed pathway elements were considered optimal for patient outcomes. But optimality is not the same as feasibility, and feasibility is a known antecedent of successful implementation. In the new secondary analysis, participants rated each element on a five-point Likert scale and provided open-ended commentary on practical obstacles. The results exposed a striking tension between what is best for patients and what health services can actually deliver. Feasibility ratings ranged from just 49.4 percent for training all clinical staff to conduct screening, up to 90.1 percent for the expectation that all health professionals validate and normalise patients’ fears.

The pattern was consistent across the pathway. Elements of the stepped-care treatment component, which matches support intensity to fear severity, attracted the highest average feasibility ratings at 75.9 percent, while the supported self-management component for moderate fear scored lowest at 61.0 percent. Resource-intensive recommendations, particularly universal training and repeated screening or booster sessions, were consistently judged least achievable. The researchers then applied directed content analysis using the updated Consolidated Framework for Implementation Research, coding 410 relevant qualitative responses across the framework’s Innovation, Individuals, Inner Setting, and Outer Setting domains. Of these, 170 were classified as barriers, 154 as enablers, and 53 as neutral factors.

The Inner Setting, meaning the organisational context of care, generated the most barriers by far, with 91 compared to just 45 enablers. Work infrastructure concerns, cited 30 times, centred on workforce capacity and the scarcity of mental health specialists, especially in regional centres where even available clinicians face demand exceeding supply. Available resources drew 31 barrier codes, reflecting worries about funding, staffing, and the cost of universal or repeated care elements. Participants also flagged equity issues, including the absence of culturally appropriate measures and the near-total lack of psychology services in rural and remote areas. By contrast, the pathway’s adaptability was the most frequently cited enabler within the Innovation domain, mentioned 22 times, with clinicians emphasising the need to tailor delivery for geographically isolated patients.

Human factors cut both ways. Screening was seen as empowering, giving patients permission to raise fears they might otherwise suppress, and the pathway’s responsiveness to patient need drew 25 enabler codes. Clinicians broadly agreed that screening falls within most staff capabilities. Yet opportunity emerged as a serious constraint: time and workload pressures limit screening opportunities, oncologists in particular are stretched thin by competing medical demands, and some participants worried that two-step screening adds administrative burden and that stepped care risks double-handling patients. There were also calls for shared decision-making, with some arguing that oncologists should only provide recurrence risk information when patients actually want it, and that treatment decisions for severe fear should involve patients as genuine partners.

From these determinants, the team used the CFIR-ERIC matching tool to link each barrier and enabler to evidence-based strategies from the Expert Recommendations for Implementing Change taxonomy. The resulting strategy set is pragmatic rather than revolutionary. Educational meetings and tailored, modular training resources should build awareness and capability across different professional roles, with online modules sufficient for triage conversations and targeted training extending the reach of nurses and allied health staff into moderate-severity interventions. Preparing local champions to model and support the pathway was proposed to overcome limited clinician opportunity, while engaging patients and families in shared decision-making addresses varied recipient needs. At the organisational level, the recommendations call for building coalitions beyond cancer centres, securing dedicated implementation funding, and aligning pathway components with existing workflows through process mapping.

Some of the most interesting implications concern workforce innovation. The authors suggest that coalitions of implementers could include trained lay workers, such as people affected by cancer themselves, who could assist with patient navigation, help identify those experiencing fear of recurrence, connect them with services, and provide emotional support. An umbrella review of patient navigation in cancer care found potential improvements in quality of life and psychological wellbeing, with no clear effectiveness difference between professional and lay navigators. Expanding primary care capacity could also relieve pressure on tertiary services, particularly for rural communities and First Nations, ethnic, and racial minority populations who may prefer community-based support. The researchers note that investment in fear-of-recurrence care may ultimately lower overall healthcare costs, strengthening the economic case for implementation.

The study has limitations worth noting. The sample, while multidisciplinary and experienced, was dominated by professionals in metropolitan public tertiary centres and lacked primary care clinicians, surgeons, palliative care specialists, patients, and cultural diversity, so findings may not generalise universally. Still, the authors argue that resource constraints appear common across settings, giving the strategies broader relevance. The bottom line is clear: a consensus-based, guideline-concordant pathway for one of cancer’s most pervasive psychological burdens now exists, and its success will depend less on the elegance of its design than on pragmatic local adaptation, prioritisation of high-impact elements, modular training, workflow integration, and system-level investment. The team’s next challenge is testing these strategies in real-world settings using hybrid effectiveness-implementation designs, so that the 30 million people living with fear of cancer’s return can finally access the care the science has long promised.

Subject of Research: Implementation of a clinical pathway for screening and stepped-care management of fear of cancer recurrence

Article Title: Designing for delivery: a Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway

Article References: Smith, B., Wu, V. S., Pearce, A., Liu, J., Shepherd, H. L., Shaw, J., Girgis, A., Garvey, G., Kirsten, L., Zakhary, I., Ee, C., Ewald, D., Miller, A., Smith, A., Virk, A. K., Gao, J., & Taylor, N. (2026). Designing for delivery: a Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway. Supportive Care in Cancer, 34(11), Article 1079. https://doi.org/10.1007/s00520-026-11275-9

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11275-9

Keywords: fear of cancer recurrence, cancer survivorship, clinical pathway, implementation science, Delphi study, stepped care, supportive care, CFIR, psychological interventions, health workforce, patient navigation, screening